Jörn Aldag, speaking at World Orphan Drug Congress 2011

Jörn Aldag,
CEO
Amsterdam Molecular Therapeutics

Mr. Aldag joined AMT in October 2009 as Chief Executive Officer. He has twenty nine years of experience in executive, business and financial management positions at Evotec AG, MAN AG and Treuhandanstalt. Over 11 years initially as CFO and then as CEO, he was instrumental in building Evotec AG into an internationally recognized biotechnology firm with more than 500 employees. Mr. Aldag is Chairman of Molecular Partners AG in Switzerland, and Member of the Supervisory Board of the DESERTEC Foundation. He holds business degrees from Harvard Business School and the European Business School.

Appearing:

World Orphan Drug Congress Day 2 Wednesday 30th November 2011

4.20pm

Case study: Challenges of ultra-orphan drug development: Glybera, a gene therapy for LPL deficiency

What were the significant challenges faced during ultra-orphan drug development?
How were clinical trials adapted to demonstrate the purpose of the treatment?
Could communication with regulatory official be improved to avoid setbacks?
How did we respond and re-evaluate to ultimately achieve market approval?

Jörn Aldag,

CEO,
Amsterdam Molecular Therapeutics

4.45pm

Panel discussion: From big pharma to niche specialist: lessons learned from rare disease collaborations

What have been the strategies of big pharma and how are they engaging in partnerships?
How are drug candidates selected for backing outside of the internal research walls?
What are the future responsibilities of patient groups within research alliances?
How do biotechs and specialised pharma companies assess potential partnering?

Dr. Alvin Shih,

Director, Orphan and Genetic Diseases,
Pfizer

Philippe Monteyne,

SVP, Head of Development & CMO,
GSK

Jörn Aldag,

CEO,
Amsterdam Molecular Therapeutics

Frédéric Revah,

CEO,
Genethon

Sponsor World Orphan Drug Congress 2011 ›

Associate Sponsor